Physician profile
Stacey A Lytle
NPI 1265989982
$5,127.27
in general payments reported to CMS, 2019-2025
38 companies · $1,231 in 2025
The $1,231 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,096 · 2022: $939 · 2023: $1,081 · 2024: $780 · 2025: $1,231.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,073 · Education: $19.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,073.00 |
| Education | $19.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,238.97 | 2021-2025 | |
| Mayne Pharma Commercial LLC | $590.42 | 2021-2025 | |
| Pfizer INC. | $324.33 | 2021-2025 | |
| Exeltis, USA INC. | $321.38 | 2021-2025 | Slynd, Twirla |
| Bayer Healthcare Pharmaceuticals INC. | $306.86 | 2021-2024 | |
| Sumitomo Pharma America, INC. | $208.33 | 2023-2025 | Myfembree, Gemtesa |
| Astellas Pharma US INC | $197.51 | 2023-2025 | Veozah |
| Avion Pharmaceuticals | $162.71 | 2021-2023 | Balcoltra |
| Hologic Sales and Service, LLC | $162.35 | 2023-2025 | Thinprep 2000 Processor, Aptima |
| Biohaven Pharmaceutical Holding Company LTD. | $149.90 | 2022 | |
| Shield Therapeutics INC | $115.14 | 2025 | |
| Daiichi Sankyo INC. | $115.10 | 2021-2024 | Injectafer |
| Sage Therapeutics, LLC | $102.88 | 2021-2025 | Zurzuvae |
| Minerva Surgical, INC | $84.05 | 2023-2024 | |
| Lilly USA, LLC | $81.47 | 2021-2025 | Zepbound, Mounjaro |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacey Lytle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.